Press Release Archives

November 9, 2007
Xanodyne Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering

October 15, 2007
XenoPort and Xanodyne Announce Exclusive U.S. Licensing Agreement for XP21510

June 19, 2007
Xanodyne Welcomes New President and CEO

February 9, 2007
Xanodyne Welcomes New Chairman of the Board

February 22, 2006
Xanodyne Pharmaceuticals to Present at Future Leaders in the Biotech Industry 2006 Conference

January 1, 2006
Xanodyne Pharmaceuticals Recruits Second Sales Force to Address Pain Markets

December 5, 2005
Xanodyne Pharmaceuticals Moves Headquarters

July 25, 2005
Xanodyne Pharmaceuticals Completes Acquisition of aaiPharma Products

July 18, 2005
Xanodyne Pharmaceuticals, Backed by MPM Capital-led Syndicate, Approved to Acquire Pain Management Portfolio

January 25, 2005
Xanodyne Pharmaceuticals Automates Field Sales Force Using Target SFA

November 16, 2004
Xanodyne Announces Fast Track Status of its Drug to Treat Heavy Menstrual Bleeding

June 1, 2004
Xanodyne Completes $20 million Series C Financing

March 24, 2004
Xanodyne Pharmaceuticals Appoints CFO for Newly Merged Corporation

February 9, 2004
Xanodyne Pharmaceuticals Completes Merger

December 4, 2003
Xanodyne Pharmacal and Integrity Pharmaceutical Corporation to Merge

September 9, 2003
Xanodyne Launches Better Tasting Amicar Syrup

August 19, 2002
Xanodyne Launches Unique Cough Product

July 18, 2002
Xanodyne Acquires New Product

January 7, 2002
Xanodyne Acquires Drug Enhancement Company of America, LLC

July 17, 2001
Xanodyne™ Pharmacal™, Inc. Formed in Northern Kentucky